Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness

NCT02978651 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Strategic decision of Sponsor

Conditions

Excessive Daytime Sleepiness
Obstructive Sleep Apnea

Interventions

DRUG: Pitolisant (BF2.649)
DRUG: Placebo Oral Tablet

Sponsor

Bioprojet